Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
Microbot Medical, a leading medical robotics company, continues to make significant strides in the development of its groundbreaking technology. Following the recent positive results of its pivotal Good Laboratory Practice (GLP) pre-clinical study, the company is now expanding its US clinical infrastructure to support the upcoming submission of its Investigational Device Exemption (IDE) for its first in human clinical study. This exciting development brings Microbot Medical one step closer to revolutionizing the field of healthcare.
In order to effectively facilitate its first in human clinical study, Microbot Medical has added a Clinical Research Associate (CRA) to its team. The role of the CRA is pivotal in ensuring the successful execution of clinical trials, managing patient recruitment, monitoring trial progress, and ensuring compliance with regulatory guidelines. By investing in additional clinical expertise, Microbot Medical aims to optimize the efficiency and accuracy of its upcoming study.
The successful completion of the GLP Pivotal Pre-Clinical Study was a critical milestone for Microbot Medical, marking a major achievement in the development of its innovative medical device. The final histopathology and laboratory report further supplements the promising findings previously announced by the company. These results provide a solid foundation for Microbot Medical’s IDE submission and instill confidence in the potential of its technology to significantly impact patient care.
Microbot Medical’s advancements in medical robotics are promising, as they hold the potential to transform the way medical procedures are performed. By utilizing cutting-edge robotic technologies, the company aims to enhance the precision, efficiency, and safety of various procedures, ultimately improving patient outcomes. With the expansion of its clinical infrastructure and the addition of a dedicated CRA, Microbot Medical is poised to take the next step towards bringing its groundbreaking technology to the market.
Comments